Pharmaceutical

A woman holding a GLP-1 weight loss drug as manufacturers developing next-generation obesity and weight loss medicines.
The race to build the next generation of weight loss drugs

The obesity drug market is entering a new phase as pharmaceutical companies race to develop oral therapies, combination treatments and next-generation medicines. With forecasts pointing to a $100 billion annual market, competition is shifting from two dominant players to a much broader field of innovators.

Roberta Loomar DifGen Pharma
Roberta Loomar is a GC Unafraid of Bringing Decades of Experience to a Rising DifGen

Roberta Loomar challenges herself by taking legal leadership of a company just this side of “startup”